Browse NUDT11

Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF00293 NUDIX domain
Function

Cleaves a beta-phosphate from the diphosphate groups in PP-InsP5 (diphosphoinositol pentakisphosphate), suggesting that it may play a role in signal transduction. Also able to catalyze the hydrolysis of dinucleoside oligophosphates, with Ap6A and Ap5A being the preferred substrates. The major reaction products are ADP and p4a from Ap6A and ADP and ATP from Ap5A. Also able to hydrolyze 5-phosphoribose 1-diphosphate.

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006152 purine nucleoside catabolic process
GO:0006195 purine nucleotide catabolic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009125 nucleoside monophosphate catabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009128 purine nucleoside monophosphate catabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009154 purine ribonucleotide catabolic process
GO:0009158 ribonucleoside monophosphate catabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009164 nucleoside catabolic process
GO:0009166 nucleotide catabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009169 purine ribonucleoside monophosphate catabolic process
GO:0009261 ribonucleotide catabolic process
GO:0015959 diadenosine polyphosphate metabolic process
GO:0015961 diadenosine polyphosphate catabolic process
GO:0019439 aromatic compound catabolic process
GO:0019751 polyol metabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0042278 purine nucleoside metabolic process
GO:0042454 ribonucleoside catabolic process
GO:0043647 inositol phosphate metabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046130 purine ribonucleoside catabolic process
GO:0046434 organophosphate catabolic process
GO:0046700 heterocycle catabolic process
GO:0071543 diphosphoinositol polyphosphate metabolic process
GO:0072523 purine-containing compound catabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901292 nucleoside phosphate catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901657 glycosyl compound metabolic process
GO:1901658 glycosyl compound catabolic process
GO:1901906 diadenosine pentaphosphate metabolic process
GO:1901907 diadenosine pentaphosphate catabolic process
GO:1901908 diadenosine hexaphosphate metabolic process
GO:1901909 diadenosine hexaphosphate catabolic process
GO:1901910 adenosine 5'-(hexahydrogen pentaphosphate) metabolic process
GO:1901911 adenosine 5'-(hexahydrogen pentaphosphate) catabolic process
Molecular Function GO:0000298 endopolyphosphatase activity
GO:0004551 nucleotide diphosphatase activity
GO:0008486 diphosphoinositol-polyphosphate diphosphatase activity
GO:0034431 bis(5'-adenosyl)-hexaphosphatase activity
GO:0034432 bis(5'-adenosyl)-pentaphosphatase activity
GO:0050072 m7G(5')pppN diphosphatase activity
GO:0052840 inositol diphosphate tetrakisphosphate diphosphatase activity
GO:0052841 inositol bisdiphosphate tetrakisphosphate diphosphatase activity
GO:0052842 inositol diphosphate pentakisphosphate diphosphatase activity
GO:0052843 inositol-1-diphosphate-2,3,4,5,6-pentakisphosphate diphosphatase activity
GO:0052844 inositol-3-diphosphate-1,2,4,5,6-pentakisphosphate diphosphatase activity
GO:0052845 inositol-5-diphosphate-1,2,3,4,6-pentakisphosphate diphosphatase activity
GO:0052846 inositol-1,5-bisdiphosphate-2,3,4,6-tetrakisphosphate 1-diphosphatase activity
GO:0052847 inositol-1,5-bisdiphosphate-2,3,4,6-tetrakisphosphate 5-diphosphatase activity
GO:0052848 inositol-3,5-bisdiphosphate-2,3,4,6-tetrakisphosphate 5-diphosphatase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1483249: Inositol phosphate metabolism
R-HSA-1430728: Metabolism
R-HSA-1855167: Synthesis of pyrophosphates in the cytosol
Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NUDT11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NUDT11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -1.99; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NUDT11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3760.293
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0390.0879
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0980.87
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.8090.394
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0040.998
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.820.237
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.8220.142
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.790.371
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7720.389
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1070.891
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3230.176
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4080.149
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NUDT11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NUDT11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NUDT11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NUDT11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NUDT11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NUDT11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NUDT11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNUDT11
Namenudix (nucleoside diphosphate linked moiety X)-type motif 11
Aliases DIPP3b; FLJ10628; hDIPP3beta; DIPP3beta; DIPP-3-beta; DIPP3-beta; diadenosine 5',5'''-P1,P6-hexaphosphate hy ......
Chromosomal LocationXp11.22-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NUDT11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.